Patents Assigned to Yeda Research & Development
-
Publication number: 20240167176Abstract: The present invention provides a stirring-free scalable electrochemical reactor enabled by alternating current and uses thereof in a method of performing electrosynthesis of organic reaction.Type: ApplicationFiled: October 19, 2023Publication date: May 23, 2024Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Sergey N. SEMENOV, Evgenil BORTNIKOV
-
Publication number: 20240165027Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.Type: ApplicationFiled: January 29, 2024Publication date: May 23, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Jacob KLEIN, Ronit GOLDBERG, Jasmine SEROR
-
Publication number: 20240166768Abstract: Monoclonal antibodies for the treatment of ovarian cancer are provided also provide are uses of same. Such uses include characterizing the tumor, diagnosing it and treatment of same.Type: ApplicationFiled: February 2, 2024Publication date: May 23, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Irit SAGI, Roei David MAZOR, Ziv SHULMAN
-
Patent number: 11986488Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.Type: GrantFiled: November 5, 2020Date of Patent: May 21, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Idit Shachar, Hadas Lewinsky, Lihi Radomir, Anna Wiener
-
Publication number: 20240156959Abstract: A method of treating cancer in a subject in need thereof is disclosed wherein cancer cells of the subject express an EGFR having a mutation in a kinase domain of the receptor. The method comprises administering to the subject a therapeutically effective amount of: (i) an anti-epidermal growth factor receptor (anti-EGFR) antibody; (ii) an AXL inhibitor, and optionally (iii) a tyrosine kinase inhibitor (TKI). Also disclosed is a new anti-AXL antibody.Type: ApplicationFiled: December 19, 2023Publication date: May 16, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef YARDEN, Ashish NORONHA
-
Patent number: 11982566Abstract: A system for photon correlation of an illuminated object and/or a light source is provided. The system includes a light source for illuminating the object and an optical system having an object-facing side configured to face the object or the light source and a projection side with the projection side having a focal plane. The system also includes a single-chip single photon avalanche photodiode (SPAD) array arranged at the focal plane and a timing circuit associated with the single-chip SPAD array for measuring arrival times of photons detected by the single-chip SPAD array.Type: GrantFiled: February 28, 2020Date of Patent: May 14, 2024Assignees: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL), YEDA RESEARCH & DEVELOPMENT CO. LTD.Inventors: Ivan Michel Antolovic, Claudio Bruschini, Edoardo Charbon, Gur Lubin, Ron Tenne, Dan Oron, Uri Rossman
-
Patent number: 11983607Abstract: A quantum computing system, method and computer readable storage medium involve tuning a whispering-gallery mode optical resonator to support a resonance frequency associated with a transition frequency of an atom. Operation of a laser is controlled to cause the atom to be trapped adjacent the optical resonator and within the evanescent field portion. Based on an atom presence signal from an optical atom presence detector, an indication is provided that the atom is trapped adjacent the optical resonator. A frequency of a cooling laser is controlled to cool the atom, and the optical resonator is configured to define a closed loop-like mode including an evanescent field portion. The trapping laser is configured to cause the atom to be trapped adjacent the whispering-gallery mode resonator, and the cooling laser is configured to manipulate a state of the atom to thereby cool the atom.Type: GrantFiled: April 14, 2023Date of Patent: May 14, 2024Assignees: Yeda Research and Development Co. Ltd., Quantum Source Labs Ltd.Inventors: Gil Semo, Ziv Aqua, Oded Melamed, Dan Charash, Serge Rosenblum, Barak Dayan
-
Publication number: 20240148845Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.Type: ApplicationFiled: November 21, 2023Publication date: May 9, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Yair REISNER, Noga OR-GEVA, Eran OPHIR, Yaki EIDELSTEIN, Rotem GIDRON BUDOVSKY
-
Patent number: 11977955Abstract: A quantum computing system comprises a plurality of photonic cavities, a plurality of coupling locations for quantum emitter positioning, a photon generator configured to supply photons to the plurality of photonic cavities, and a plurality of photon output channels downstream of the plurality of cavities to output a graph state. Each coupling location is associated with a differing one of the plurality of photonic cavities. Quantum emitters associated with each coupling location are configured to mediate interactions between consecutive incoming photonic qubits to generate the graph state, and the photonic cavities are configured to couple photonic qubits to the quantum emitters.Type: GrantFiled: April 13, 2023Date of Patent: May 7, 2024Assignees: Yeda Research and Development Co. Ltd., Quantum Source Labs Ltd.Inventors: Gil Semo, Ziv Aqua, Oded Melamed, Dan Charash, Serge Rosenblum, Barak Dayan
-
Publication number: 20240139326Abstract: This invention is directed to substituted a methacrylamide compounds as targeted covalent protein binders and uses thereof.Type: ApplicationFiled: December 23, 2021Publication date: May 2, 2024Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Nir LONDON, Efrat RESNICK, Rambabu REDDI, Adi ROGEL
-
Publication number: 20240140988Abstract: A method of isolating an antibody is disclosed. The method comprises contacting a hydrophobic chelator, a non-ionic detergent and metal ions so as to generate an aggregate comprising the hydrophobic chelator, the detergent and the metal ions; and contacting the aggregate with a medium comprising the antibody under conditions that allow partitioning of the antibody into the aggregate. Kits for isolating the antibody are also disclosed.Type: ApplicationFiled: April 16, 2020Publication date: May 2, 2024Applicants: Ariel Scientific Innovations Ltd., Yeda Research and Development Co. Ltd.Inventors: Guy PATCHORNIK, Mordechai SHEVES, Irishi N. N. NAMBOOTHIRI, Gunasekaran DHANDAPANI
-
Patent number: 11972324Abstract: Generating photonic graph states includes positioning a plurality of quantum emitters at a plurality of coupling sites associated with a plurality of cavities and initializing a state of a quantum emitter qubit associated with each of the plurality of quantum emitters. Photonic qubits are transmitted toward the plurality of the quantum emitters a first instance transmission for generating an entangling gate between the photonic qubits and the quantum emitter qubit in order to entangle the quantum emitter qubit and the photonic qubits. Following the first instance transmission, photonic qubits are transmitted toward the plurality of quantum emitters in a one second instance transmission for generating a SWAP gate between the photonic qubits and the quantum emitter qubits to map the quantum emitter qubits to photonic qubits.Type: GrantFiled: April 13, 2023Date of Patent: April 30, 2024Assignees: Yeda Research and Development Co. Ltd., Quantum Source Labs Ltd.Inventors: Gil Semo, Ziv Aqua, Oded Melamed, Dan Charash, Serge Rosenblum, Barak Dayan
-
Publication number: 20240133870Abstract: Combined treatment for cancer is provided. Accordingly, there is provided a method of selecting or determining therapeutic efficacy of a combination of agents for the treatment of cancer in a subject in need thereof, the method comprising: (i) culturing a cancerous tissue of the subject in an ex-vivo organ culture (EVOC) in the presence of a combination of an anti-cancer agent and an additional agent, said additional agent is inhibiting expression and/or activity of a target conferring innate resistance to said anti-cancer agent or increasing expression and/or activity of a target conferring innate sensitivity to said anti-cancer agent; and (ii) determining an anti-cancer effect of the combination on the tissue, wherein responsiveness of the tissue to the combination indicates the combination is efficacious for the treatment of the cancer in the subject.Type: ApplicationFiled: December 6, 2023Publication date: April 25, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Ravid STRAUSSMAN, Oded SANDLER
-
Patent number: 11965885Abstract: Methods and kits for diagnosing or monitoring systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing or monitoring SLE in a subject.Type: GrantFiled: May 27, 2021Date of Patent: April 23, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Rachel Sorek, Keren Jakobi, Pennina Safer, Anat Reiner-Benaim, Irun R. Cohen
-
Publication number: 20240127099Abstract: A quantum computing system includes a first resonator couplable to a first alkali atom, a second resonator couplable to a second alkali atom, and lasers for trapping, cooling, and manipulating the first alkali atom and the second alkali atom. Detectors detect a presence of the trapped first alkali atom and the trapped second alkali atom, and a processor is configured to receive at least one input signal from at least one of the detectors, the input signal indicating a presence of the trapped first alkali atom and the trapped second alkali atom, and, based on the received input, control at least some of the lasers to manipulate at least one of the trapped first alkali atom and the trapped second alkali atom to thereby generate photonic qubits using the trapped first alkali atom or generate entanglement between photonic qubits transmitted to the trapped second alkali atom.Type: ApplicationFiled: October 10, 2023Publication date: April 18, 2024Applicants: QUANTUM SOURCE LABS LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Gil SEMO, Ziv AQUA, Oded MELAMED, Dan CHARASH, Serge ROSENBLUM, Barak DAYAN
-
Patent number: 11959097Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.Type: GrantFiled: July 27, 2023Date of Patent: April 16, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Yaqub Hanna, Sergey Viukov, Emilie Wildschutz, Noa Novershtern, Carine Joubran, Segev Naveh Tassa, Alejandro Castrejon Aguilera, Bernardo Oldak, Shadi Tarazi, Francesco Roncato
-
Patent number: 11957102Abstract: The present invention relates to key genes in the biosynthesis of steroidal alkaloids and saponins, including regulatory genes and enzyme-encoding genes, and to use thereof for altering the content of steroidal (glyco)alkaloids or phytosterols in plants. The present invention provides genetically modified plants or gene edited plants with altered content of steroidal (glyco)alkaloids, particularly to Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids and to the increase in phytosterols, including cholesterol or cholestanol in these plants. The present invention also provides methods of altering gene expression.Type: GrantFiled: July 7, 2022Date of Patent: April 16, 2024Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Asaph Aharoni, Prashant Sonawane, Maxim Itkin
-
Publication number: 20240117386Abstract: A recombinant bacteria which is genetically modified to express formate dehydrogenase (FDH), phosphoribulokinase (prk) and Ribulose-Bisphosphate Carboxylase/oxygenase (RuBisCo) is disclosed. The bacteria may be modified to be autotrophic.Type: ApplicationFiled: October 22, 2020Publication date: April 11, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Ron MILO, Shmuel GLEIZER, Niv ANTONOVSKY, Elad NOOR, Arren BAR-EVEN, Yehudit ZOHAR, Roee BEN NISSAN, Elad HERZ, Yinon Moise BAR-ON
-
Patent number: 11944644Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.Type: GrantFiled: December 4, 2018Date of Patent: April 2, 2024Assignees: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER, YEDA RESEARCH AND DEVELOPMENT CO. LTDInventors: Zelig Eshhar, Tova Waks, Anat Globerson Levin, Moran Rawet Slobodkin
-
Publication number: 20240094224Abstract: Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue. Also provided are methods for determination of disease severity and chronology.Type: ApplicationFiled: November 29, 2023Publication date: March 21, 2024Applicant: Yeda Research and Development Co. Ltd.Inventors: Eran ELINAV, Alon SAVIDOR